Home » COMPANY » News & Events » NEWS » 셀레믹스 “내년 혈액암 면역 레퍼토어 분석 솔루션 내놔”
News & Events
View the various news of Celemics
The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >Hybridization-based target enrichment panel with our intrinsic probe design, rebalancing, and molecular barcode technologies to efficiently analyze not only hard-to-capture areas but also challenging samples, such as damaged DNA or RNA.
View Detail >End-to-end customized target enrichment panel with assay optimization, validation and even complete BI support. Over 1,000 custom panels developed world-wide. White-labeled customized product for business expansion also available.
View Detail >Revolutionary Bioinformatics solution providing fast and
accurate, client-specific analysis services.
Trust CAS with your BI analysis !
Highly optimized library preparation kit to be used with all Celemics ready-to-use or customized panels. Experience the incomparable efficiency and performance for NGS library preparation
View Detail >The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >Celemics’ comprehensive NGS panel for somatic cancer allows highly accurate and comprehensive analysis for identifying significant mutations and variants for solid tumors.
Celemics’ comprehensive NGS panel for somatic cancer allows highly accurate and comprehensive analysis for identifying significant mutations and variants for solid tumors.
Celemics has developed NGS ctDNA-based kits for colon, breast, and lung cancer assays. We have integrated our market-leading proprietary technologies and thoroughly validated and optimized as ready-to-use panels for clinical diagnostics.
Celemics offers end-to-end NGS-based detection and discovery solutions for Biopharma, CRO, and Drug discovery research fields.
In order to overcome the limitations of analyzing clinical diseases with conventional whole exome sequencing, Celemics introduces NGS-based clinical diagnostic solution for efficient detection of disease-causing variants for inherited diseases.
Celemics offers flexible choice of assessing extensive target regions associated with Pharmacogenomics for client-specific drug prescription and drug metabolism.
Celemics’ virus panels are designed to detect and identify disease-causing viruses. With our exclusive technologies, we provide efficient and accurate detection of targeted virus trains as well as procurement of credible data for whole viral genome sequencing.
To fulfill the expectations and growing needs for sequencing animals and plants, Celemics offers range of ready-to-use applicable to agrigenomics field as well as an option for developing customized NGS panel to specifically fit individual research purposes.
With Celemics’ proprietary technologies for assay development and optimization, we offer complete and robust NGS solutions for transcriptome, fusion, and isoform analyses for various sample types and conditions.
Celemics provides comprehensive solution for DNA methylation sequencing with proprietary probes specifically designed for methyl-seq, enabling accurate detection of methylation sites.
Complete solution with flexible panel design for characterization and differentiation of a myriad of microbial species.
Accurate and efficient analysis of IGH population that can detect MRD as low as 10-6 with optimized primers that can minimize sequencing loss and PCR duplications.
Celemics introduces revolutionary BI solution aiming to provide client-specific service. We provide fast, accurate, and sophisticated analyses of your NGS data accompanied by our proprietary bioinformatics pipeline.
The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >End-to-end customized target enrichment panel with assay optimization, validation and even complete BI support. Over 1,000 custom panels developed world-wide. White-labeled customized product for business expansion also available.
View Detail >Utilizing NGS-based target enrichment methods for higher genotyping efficiency and accuracy. Providing cost-effective and optimized experiment compared to conventional methods, such as GBS, PCR and microarray in plant and animal research
View Detail >Providing NGS-based diagnostics solutions for biopharma companies. Celemics can develop and deliver a flexible customization and commercialization services while maintaining the market-leading performance for our clients interested in clinical and companion diagnostics.
View Detail >Tailored-fit customized assay development from designing to validation run; including not only the custom panel design but also species-specific or sequencer-specific blockers, followed by reagent conditioning to optimize the individual experiment and sequencer.
View Detail >The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >Find useful information, insights and tools for your Celemics’ products and services
View Detail >Explore the most up-to-date publications featuring Celemics’ products and services
View Detail >Sharing interesting stories about the world of NGS and how Celemics delivers the innovative NGS solutions to the world of science.
View Detail >Find useful information, insights and tools for your Celemics’ products and services
View Detail >In-silico designed and wet-lab validated exclusive probes to ensure state-of-the-art capture performance
View Detail >Stay up-to-date with the latest updates on our activities, events and achievements
View Detail >Let’s change the NGS market together – our global presence and partners world-wide
View Detail >Waiting for your experience with Celemics, an innovative leader in NGS industry
View Detail >Home » COMPANY » News & Events » NEWS » 셀레믹스 “내년 혈액암 면역 레퍼토어 분석 솔루션 내놔”
News & Events
View the various news of Celemics
김효기 셀레믹스 대표는 28일 서울 한강로 드래곤시티에서 ‘2020 대한민국 바이오 투자 콘퍼런스(KBIC)’에서 내년 하반기에 차세대염기서열분석(NGS) 기술을 기반으로 한 혈액암 면역 레퍼토어 분석 솔루션을 내놓겠다고 발표했다.
김 대표는 “NGS기술을 기반으로 한 DNA처리 시약 대부분은 올해 연구개발이 완료돼 매출이 나고 있다”며 “혈액암 치료 효과 점검(모니터링)과 재발 모니터링을 할 수 있는 기술을 내년에 상용화할 예정”이라고 말했다.
NGS는 다양한 DNA와 RNA, 바이러스 등의 전체 염기서열을 밝힐 수 있는 유전자 검사 방식이다.
셀레믹스는 최근 한 번에 동시에 9개의 바이러스를 한꺼번에 검출 할 수 있는 호흡기 바이러스 분석 패널을 출시했다. 신종 코로나바이러스 감염증(코로나19) 뿐 아니라 다른 호흡기 바이러스 검출도 가능하다. 이 패널에는 셀레믹스 고유의 ‘하이브리다이제이션 인핸서’ 기술이 적용된다. 기존 NGS 방식보다 4배 빠르게 검사 결과를 확인할 수 있다.
김 대표는 “현재 15개국에서 제품을 판매하고 수익을 내고 있다”며 “수익을 늘리기 위해 다양한 국가에서 우리 제품을 알리는 데 노력할 것”이라고 했다.